Edaravone Dexborneol + Placebo
Phase 2UNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 31/100
31
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Intracerebral Hemorrhage
Conditions
Intracerebral Hemorrhage
Trial Timeline
Mar 1, 2021 → Sep 1, 2023
NCT ID
NCT04714177About Edaravone Dexborneol + Placebo
Edaravone Dexborneol + Placebo is a phase 2 stage product being developed by Sun Pharmaceutical for Intracerebral Hemorrhage. The current trial status is unknown. This product is registered under clinical trial identifier NCT04714177. Target conditions include Intracerebral Hemorrhage.
What happened to similar drugs?
0 of 2 similar drugs in Intracerebral Hemorrhage were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
12
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04714177 | Phase 2 | UNKNOWN |
Competing Products
6 competing products in Intracerebral Hemorrhage
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| NXY-059 | AstraZeneca | Phase 2 | 35 |
| Recombinant Factor VIIa + Biological/Vaccine: Placebo | Novo Nordisk | Phase 3 | 47 |
| Recombinant Activated Factor VII (rFVIIa) + Placebo | Novo Nordisk | Phase 3 | 44 |
| PF-05230907 | Pfizer | Phase 1 | 21 |
| CN-105 | Tiantan Bio | Phase 2 | 28 |
| Albumin + Placebo | Baxter | Phase 2 | 24 |